title: Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse.
abstract: Vascular endothelial growth factor (VEGF) is a growth factor that contributes to the angiogenesis of developing tumors. To interfere with the action of VEGF, a nuclease-stabilized ribozyme, ANGIOZYME, has been developed against VEGF receptor subtype Flt-1 mRNA. To determine which routes of administration would be useful for systemic delivery of this ribozyme, a dose of 30 mg/kg [32P]ANGIOZYME was administered as an i.v., i.p., or s.c. bolus. Concentrations of ANGIOZYME in plasma, femur, kidney, liver, and lung were examined. ANGIOZYME was well absorbed after i.p. (90%) or s.c. administration (77%), with peak plasma concentrations occurring 30 minutes after dosing. Total body clearance after a single dose of 30 mg/kg ANGIOZYME was 20 ml/min/kg, and the elimination half-life was 33 minutes. The apparent volume of distribution at steady-state ranged from 0.5 to 1.3 L/kg. ANGIOZYME was detected in the four tissues examined through the 3 hour sampling period after i.v. or i.p. administration. After s.c. administration, ANGIOZYME was detected in femur, kidney, and lung but not in the liver. The highest concentrations of ANGIOZYME were found in kidney and femur with all three routes. Because of the rapid and extensive absorption after extravascular injections, either i.p. or s.c. administration could be considered for use in pharmacodynamic studies examining the effects of ANGIOZYME or other ribozymes with similar chemical modifications.
authors.affiliation: Ribozyme Pharmaceuticals, Inc., Boulder, CO 80301, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Sandberg
authors.forename: K S
authors.initials: KS
authors.lastname: Bouhana
authors.forename: A M
authors.initials: AM
authors.lastname: Gallegos
authors.forename: A B
authors.initials: AB
authors.lastname: Agrawal
authors.forename: S L
authors.initials: SL
authors.lastname: Grimm
authors.forename: F E
authors.initials: FE
authors.lastname: Wincott
authors.forename: M A
authors.initials: MA
authors.lastname: Reynolds
authors.forename: P A
authors.initials: PA
authors.lastname: Pavco
authors.forename: T J
authors.initials: TJ
authors.lastname: Parry
mesh_terms: D000818:Animals; D005260:Female; D006207:Half-Life; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D016337:RNA, Catalytic / Q000493:pharmacokinetics* / Q000494:pharmacology; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D017978:Receptors, Growth Factor / Q000235:genetics; D040262:Receptors, Vascular Endothelial Growth Factor; D014018:Tissue Distribution
chemical_list: C121301:Angiozyme; D016337:RNA, Catalytic; D012333:RNA, Messenger; D017978:Receptors, Growth Factor; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor